This report describes myopathy, lactic acidosis, and sideroblastic anemia 3 (MLASA3), which is a subtype of myopathy, lactic acidosis, and sideroblastic anemia (MLASA). It is one of several diseases associated with the human mitochondrially-encoded gene MT-ATP6. See the human disease model report for mitochondrial complex V disorders, MT-ATP6-related (FBhh0000376) for information on experimental results using Drosophila models of this and related diseases. See MIM:516060 for variants of MT-ATP6 associated with myopathy, lactic acidosis, and sideroblastic anemia 3.
[updated Aug. 2016 by FlyBase; FBrf0222196]
MLASA3 is a severe mitochondrial disorder with early infantile presentation of transfusion-dependent sideroblastic anemia in the setting of failure to thrive, hearing loss, epilepsy, stroke-like episodes, and severe developmental delay (summary by Burrage et al., 2014; pubmed:25037980). [from MIM:500011; 2016.08.26]
MLASA3 is caused by heteroplasmic mutation in the mitochondrial-encoded ATP6 gene (MT-ATP6). One such patient has been reported. [from MIM:500011; 2016.08.26]
Many to one: 2 human to 1 Drosophila; the additional orthologous human gene is MT-ATP8.